- The tetracycline antibiotics, including
minocycline and doxycycline, have
immunomodulatory and neuroprotective
activities. They appear to decrease the passage
of lymphocytes across the blood-brain barrier. A
small Phase II trial of Copaxone plus minocycline
showed favorable MRI data.
- In a small trial in patients with RRMS, minocycline
decreased gadolinium-enhancing activity by 50
percent over a period of six months. A
subsequent 24-month trial showed a significant
decrease in lesion activity and clinical status.
- A Phase III trial with 200 participants is studying
the effect of 100 mg of oral minocycline twice
daily on the conversion of clinically isolated
syndrome (CIS) to a diagnosis of MS at six and
24 months. It began in January 2009 and is
scheduled for completion in December 2015. It
will determine whether 100 mg of oral
minocycline twice daily reduces the conversion
of clinically isolated syndrome (CIS) to clinically
active MS and if any treatment benefit seen after
six months is maintained at two years.
- A small Phase IV study combining doxycycline
with Avonex demonstrated a statistically
significant reduction of gadolinium-enhancing
lesions compared with Avonex alone. A larger
trial is needed to confirm these results.